127 related articles for article (PubMed ID: 37667539)
1. Trends in epidemiology and risk factors of opportunistic infections in kidney transplant recipients between 2004 and 2017.
Pfirmann P; Garrigue I; Chauveau B; Rondeau V; Tumiotto C; Weinmann L; Dubois V; Couzi L; Merville P; Kaminski H; Taton B
Nephrol Dial Transplant; 2024 Mar; 39(4):627-636. PubMed ID: 37667539
[TBL] [Abstract][Full Text] [Related]
2. Viral infection in renal transplant recipients.
Cukuranovic J; Ugrenovic S; Jovanovic I; Visnjic M; Stefanovic V
ScientificWorldJournal; 2012; 2012():820621. PubMed ID: 22654630
[TBL] [Abstract][Full Text] [Related]
3. Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort.
Pullerits K; Garland S; Rengarajan S; Guiver M; Chinnadurai R; Middleton RJ; Chukwu CA; Kalra PA
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366504
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus infection in kidney transplant patients: Prevalence, risk factors, and impact on outcome - A local multicentre experience.
Abou-Jaoudé M; El Hage S; Akiki D; Fadlallah M; Ghaith AK; Dib A
Transpl Immunol; 2021 Dec; 69():101473. PubMed ID: 34547416
[TBL] [Abstract][Full Text] [Related]
5. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
Shah AP; Chen JM; Fridell JA
Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
[TBL] [Abstract][Full Text] [Related]
6. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
Mabilangan C; Preiksaitis JK; Cervera C;
Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
[TBL] [Abstract][Full Text] [Related]
7. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
George MJ; Snydman DR; Werner BG; Griffith J; Falagas ME; Dougherty NN; Rubin RH
Am J Med; 1997 Aug; 103(2):106-13. PubMed ID: 9274893
[TBL] [Abstract][Full Text] [Related]
8. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
Mabilangan C; Preiksaitis J; Cervera C;
Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
[TBL] [Abstract][Full Text] [Related]
9. Human Leukocyte Antigen Alleles and Cytomegalovirus Infection After Renal Transplantation.
Futohi F; Saber A; Nemati E; Einollahi B; Rostami Z
Nephrourol Mon; 2015 Nov; 7(6):e31635. PubMed ID: 26866009
[TBL] [Abstract][Full Text] [Related]
10. Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation.
Robinson LG; Hilinski J; Graham F; Hymes L; Beck-Sague CM; Hsia J; Nesheim SR
Pediatr Transplant; 2002 Apr; 6(2):111-8. PubMed ID: 12000465
[TBL] [Abstract][Full Text] [Related]
11. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection in renal transplant recipients: one center's experience.
Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
[TBL] [Abstract][Full Text] [Related]
13. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
[TBL] [Abstract][Full Text] [Related]
14. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(4):1-56. PubMed ID: 23074407
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
16. Infections in the first year after renal transplant.
Saad EJ; Fernández P; Cardozo Azua AE; Ellena V; Diz C; Giordano G; Borgogno P; Nuñez S; Sarmantano D; Guzman A; Schwarz F; Naser S; Flores MF; Alaye ML; Caeiro JP; De la Fuente J
Medicina (B Aires); 2020; 80(6):611-621. PubMed ID: 33254105
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors.
Cordero E; Casasola C; Ecarma R; Danguilan R
Transplant Proc; 2012 Apr; 44(3):694-700. PubMed ID: 22483471
[TBL] [Abstract][Full Text] [Related]
18. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
20. Antithymocyte induction dosing and incidence of opportunistic viral infections using steroid-free maintenance immunosuppression.
Von Stein L; Leino AD; Pesavento T; Rajab A; Winters H
Clin Transplant; 2021 Jan; 35(1):e14102. PubMed ID: 32985025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
